Summary of COVID-19 AER002 studies

1. Peluso et al., A phase 2a double-blind, placebo-controlled randomized trial of the SARS-CoV-2-specific monoclonal antibody AER002 in people with Long COVID

36 patient AER002 late treatment RCT: 6% higher long COVID (p=0.25).
RCT 36 long COVID outpatients showing no significant clinical benefit with the AER002 monoclonal antibody compared to placebo.
Oct 2025, medRxiv, https://www.medrxiv.org/content/10.64898/2026.03.07.26347857, https://c19p.org/peluso3